Interleukin-4 Receptor alpha Subunit
"Interleukin-4 Receptor alpha Subunit" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A receptor subunit that is a component of the TYPE I INTERLEUKIN-4 RECEPTOR and the TYPE II INTERLEUKIN-4 RECEPTOR. It signals through interaction of its cytoplasmic domain with JANUS KINASES such as JANUS KINASE 1.
| Descriptor ID |
D053662
|
| MeSH Number(s) |
D12.776.543.750.705.852.420.360.300.200 D12.776.543.750.705.852.420.360.600.200 D12.776.543.750.705.852.420.600.800.200
|
| Concept/Terms |
Interleukin-4 Receptor alpha Subunit- Interleukin-4 Receptor alpha Subunit
- Interleukin 4 Receptor alpha Subunit
- Antigens, CD124
- CD124 Antigens
- Interleukin-4 Receptor alpha Chain
- Interleukin 4 Receptor alpha Chain
- alpha-subunit, Receptor, Interleukin-4
- Interleukin-4 Receptors alpha
- Interleukin 4 Receptors alpha
- Receptors alpha, Interleukin-4
- Receptor, Interleukin-4, alpha Subunit
- CD124 Antigen
- Antigen, CD124
|
Below are MeSH descriptors whose meaning is more general than "Interleukin-4 Receptor alpha Subunit".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptors, Immunologic [D12.776.543.750.705]
- Receptors, Cytokine [D12.776.543.750.705.852]
- Receptors, Interleukin [D12.776.543.750.705.852.420]
- Receptors, Interleukin-4 [D12.776.543.750.705.852.420.360]
- Receptors, Interleukin-4, Type I [D12.776.543.750.705.852.420.360.300]
- Interleukin-4 Receptor alpha Subunit [D12.776.543.750.705.852.420.360.300.200]
- Receptors, Interleukin-4, Type II [D12.776.543.750.705.852.420.360.600]
- Interleukin-4 Receptor alpha Subunit [D12.776.543.750.705.852.420.360.600.200]
- Receptors, Interleukin-13 [D12.776.543.750.705.852.420.600]
- Receptors, Interleukin-4, Type II [D12.776.543.750.705.852.420.600.800]
- Interleukin-4 Receptor alpha Subunit [D12.776.543.750.705.852.420.600.800.200]
Below are MeSH descriptors whose meaning is more specific than "Interleukin-4 Receptor alpha Subunit".
This graph shows the total number of publications written about "Interleukin-4 Receptor alpha Subunit" by people in this website by year, and whether "Interleukin-4 Receptor alpha Subunit" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 4 | 4 |
| 2018 | 2 | 1 | 3 |
| 2019 | 2 | 4 | 6 |
| 2020 | 1 | 2 | 3 |
| 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Interleukin-4 Receptor alpha Subunit" by people in Profiles.
-
Reactivation of Alopecia Areata After Dupilumab Therapy for Atopic Dermatitis. Dermatitis. 2021 Oct 01; 32(1S):e80-e82.
-
Management of adult patients with severe atopic dermatitis treated with dupilumab during COVID-19 pandemic: A single-center real-life experience. Dermatol Ther. 2020 Jul; 33(4):e13765.
-
No evidence of increased risk for Coronavirus Disease 2019 (COVID-19) in patients treated with Dupilumab for atopic dermatitis in a high-epidemic area - Bergamo, Lombardy, Italy. J Eur Acad Dermatol Venereol. 2020 Sep; 34(9):e433-e434.
-
Assessing the risk of dupilumab use for atopic dermatitis during the COVID-19 pandemic. J Am Acad Dermatol. 2020 09; 83(3):e251-e252.
-
Safety of dupilumab in severe atopic dermatitis and infection of Covid-19: two case reports. J Eur Acad Dermatol Venereol. 2020 Jul; 34(7):e303-e304.
-
SARS-CoV-2 asymptomatic infection in a patient under treatment with dupilumab. J Eur Acad Dermatol Venereol. 2020 Aug; 34(8):e368.
-
Dupilumab and COVID-19: What should we expect? Dermatol Ther. 2020 Jul; 33(4):e13502.
-
Pathomechanism of dupilumab-associated inflammatory eye symptoms. J Eur Acad Dermatol Venereol. 2019 Nov; 33(11):e435-e436.
-
A case of guttate psoriasis during treatment with dupilumab. Dermatol Ther. 2019 09; 32(5):e12998.
-
Rosacea associated with dupilumab therapy. J Dermatolog Treat. 2021 Feb; 32(1):114-116.